Table 2 Demographic details for PD and control patients.

From: A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells

 

Controls

LRRK2 mutation carriers

iPD

R1441G PD

R1441G NMC

G2019S PD

G2019S NMC

Participant number

10

12

9

7

6

4

Age (y)

59 ± 10.7

66.6 ± 11

58.6 ± 10.9

72 ± 10.5

57.3 ± 11

61.6 ± 9.5

Sex (% male)

40%

33%

22%

33%

33%

75%

Disease duration (y)

—

7.2 ± 5.4

—

10.7 ± 3.1

—

14.2 ± 4

Age at diagnosis (y)

—

59.6 ± 10.3

—

61.4 ± 11.1

—

47.5 ± 5.9

Disease severity

—

16.6 ± 10.2

—

19.2 ± 3.9

—

11.3 ± 3

LED

—

546 ± 359

—

788 ± 484

—

960 ± 470

  1. All participants were of Basque origin except for 2 controls (1 Spanish, 1 Romanian), one R1441G-LRRK2 PD (Spanish) and one G2019S-LRRK2 NMC (Spanish). Data shown are mean ± s.d. Disease severity was measured using the Movement Disorders Society Unified Parkinson´s Disease Rating Scale (MDS-UPDRS) part III, and LED is the calculated L-dopa-equivalent dose. All patients were sequenced for the G2019S and R1441G-LRRK2 mutations.
  2. NMC non-manifesting carriers.
Back to article page